Traditional drug development processes are plagued by exorbitant costs and prolonged timelines, presenting formidable barriers to innovation in the pharmaceutical industry. The urgent need for transformative solutions has never been more apparent, as the demand for novel therapeutics continues to ...
Only 3-5% of adult cancer patients in the U.S. and fewer than 1 in 20 globally participate in clinical trials, largely due to stringent eligibility criteria. This low enrollment highlights the complexities of oncology trials with multifaceted treatments and ethical considerations, emphasizing the ...